EA201501166A1 - Соединение гликозаминогликана, способ его получения и применение - Google Patents

Соединение гликозаминогликана, способ его получения и применение

Info

Publication number
EA201501166A1
EA201501166A1 EA201501166A EA201501166A EA201501166A1 EA 201501166 A1 EA201501166 A1 EA 201501166A1 EA 201501166 A EA201501166 A EA 201501166A EA 201501166 A EA201501166 A EA 201501166A EA 201501166 A1 EA201501166 A1 EA 201501166A1
Authority
EA
Eurasian Patent Office
Prior art keywords
drug
compound
glican
glycosamino
preparation
Prior art date
Application number
EA201501166A
Other languages
English (en)
Other versions
EA031285B1 (ru
Inventor
Хуа-Ян Линь
Original Assignee
Айхол Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Айхол Корпорейшн filed Critical Айхол Корпорейшн
Publication of EA201501166A1 publication Critical patent/EA201501166A1/ru
Publication of EA031285B1 publication Critical patent/EA031285B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретение относится к соединению, образующему конъюгат лекарственного препарата с гликозаминогликаном, например гиалуроновой кислотой (НА), в котором лекарственный препарат пригоден для лечения заболеваний, как например, воспаления, аутоиммунного заболевания, аллергии, инфекции и предпочтительно рака. Конъюгированное соединение данного изобретения может увеличить концентрацию лекарственного препарата в конкретном очаге болезни путем взаимодействия гликозаминогликана, используемого в качестве носителя целенаправленной доставки лекарственного препарата, и рецептора клеточной поверхности CD44, затем привести к улучшению терапевтической эффективности и снижению системного побочного действия доставляемого в очаг лекарственного препарата.
EA201501166A 2013-08-29 2014-08-27 Конъюгат гиалуроновой кислоты и стероида, способ его получения и применение EA031285B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361871352P 2013-08-29 2013-08-29
PCT/US2014/052813 WO2015031425A1 (en) 2013-08-29 2014-08-27 Compound of glycosaminoglycan and its preparation method as well as application

Publications (2)

Publication Number Publication Date
EA201501166A1 true EA201501166A1 (ru) 2016-10-31
EA031285B1 EA031285B1 (ru) 2018-12-28

Family

ID=52584073

Family Applications (4)

Application Number Title Priority Date Filing Date
EA201690487A EA034600B1 (ru) 2013-08-29 2014-06-27 Конъюгаты гиалуроновой кислоты с антагонистами cox-2 и их применение для лечения рака
EA201992517A EA038278B1 (ru) 2013-08-29 2014-06-27 Конъюгат гиалуроновой кислоты и леналидомида, способ его получения и применение для лечения рака
EA201992518A EA038422B1 (ru) 2013-08-29 2014-06-27 Конъюгат гиалуроновой кислоты и гемцитабина, способ его получения и применение для лечения рака
EA201501166A EA031285B1 (ru) 2013-08-29 2014-08-27 Конъюгат гиалуроновой кислоты и стероида, способ его получения и применение

Family Applications Before (3)

Application Number Title Priority Date Filing Date
EA201690487A EA034600B1 (ru) 2013-08-29 2014-06-27 Конъюгаты гиалуроновой кислоты с антагонистами cox-2 и их применение для лечения рака
EA201992517A EA038278B1 (ru) 2013-08-29 2014-06-27 Конъюгат гиалуроновой кислоты и леналидомида, способ его получения и применение для лечения рака
EA201992518A EA038422B1 (ru) 2013-08-29 2014-06-27 Конъюгат гиалуроновой кислоты и гемцитабина, способ его получения и применение для лечения рака

Country Status (19)

Country Link
US (5) US9572832B2 (ru)
EP (2) EP3038656B1 (ru)
JP (2) JP6404925B2 (ru)
KR (2) KR102283978B1 (ru)
CN (5) CN114010796A (ru)
AU (6) AU2014314536B2 (ru)
BR (2) BR112016004357B1 (ru)
CA (3) CA3133853C (ru)
DK (1) DK3038656T3 (ru)
EA (4) EA034600B1 (ru)
ES (2) ES2893329T3 (ru)
HK (2) HK1223291A1 (ru)
HU (1) HUE056434T2 (ru)
LT (1) LT3038656T (ru)
MY (1) MY180502A (ru)
PL (1) PL3038656T3 (ru)
PT (1) PT3038656T (ru)
TW (2) TWI526212B (ru)
WO (2) WO2015028172A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9572832B2 (en) * 2013-08-29 2017-02-21 Holy Stone Healthcare Co., Ltd. Compound of glycosaminoglycan and its fabrication method as well as application
EA027663B1 (ru) * 2016-05-20 2017-08-31 Тютор С.А.С.И.Ф.И.А. Способ получения твёрдой лекарственной формы для перорального применения и твёрдая лекарственная форма для перорального применения, полученная согласно указанному способу
CN113660933B (zh) 2019-06-03 2023-12-01 爱禾公司 透明质酸复合物及其用途
US11458204B2 (en) 2020-06-02 2022-10-04 Aihol Corporation Method for improving substitution rate and/or substitution efficiency of hyaluronan-drug conjugates
TWI833088B (zh) * 2020-06-08 2024-02-21 禾伸堂生技股份有限公司 透明質酸複合物及透明質酸複合物的用途
EP4355314A1 (en) * 2021-06-18 2024-04-24 Aihol Corporation Uses of hyaluronan conjugate
CN116726186A (zh) * 2022-03-11 2023-09-12 四川省医学科学院·四川省人民医院 药物递送系统及其在制备抗黑色素瘤药物中的应用
PL442924A1 (pl) * 2022-11-23 2024-05-27 Politechnika Śląska Prolek - glikokoniugat pochodny gemcytabiny, jako związek o działaniu przeciwnowotworowym, sposób otrzymywania i zastosowanie

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8713662D0 (en) * 1987-06-11 1987-07-15 Skandigen Ab Hyaluronic acid derivatives
US5733891A (en) * 1990-10-18 1998-03-31 Shiseido Co., Ltd. Compound for medicinal ingredient and hyaluronic acid and process for producing the same
JPH0585942A (ja) * 1991-02-26 1993-04-06 Denki Kagaku Kogyo Kk インターフエロン−ヒアルロン酸及び／又はその塩の結合体
JPH0673103A (ja) * 1991-11-27 1994-03-15 Lignyte Co Ltd ヒアルロン酸高分子複合体及びその製造方法
WO1994009811A1 (en) 1992-10-30 1994-05-11 Duke University An adhesion molecule
US5616568A (en) * 1993-11-30 1997-04-01 The Research Foundation Of State University Of New York Functionalized derivatives of hyaluronic acid
WO1999045942A1 (en) 1998-03-13 1999-09-16 Entremed, Inc. Metastatin and hyaluronate binding proteins and methods of use
CA2332802A1 (en) * 1998-05-20 1999-11-25 Chugai Seiyaku Kabushiki Kaisha Conjugate of therapeutic agent for joint disease and hyaluronic acid
ITPD980169A1 (it) * 1998-07-06 2000-01-06 Fidia Advanced Biopolymers Srl Ammidi dell'acido ialuronico e dei suoi derivati e processo per la loro preparazione.
GB9902412D0 (en) * 1999-02-03 1999-03-24 Fermentech Med Ltd Process
JP2001081103A (ja) * 1999-09-13 2001-03-27 Denki Kagaku Kogyo Kk ヒアルロン酸結合薬剤
JP4266571B2 (ja) * 2002-05-17 2009-05-20 生化学工業株式会社 脂質結合グリコサミノグリカンの製造法
AU2003265576A1 (en) * 2002-08-23 2004-03-11 The Mclean Hospital Corporation Corticosteroid conjugates and uses thereof
US8192744B2 (en) 2002-08-26 2012-06-05 Ibcc Holding As Drug for treating states related to the inhibition of angiogenesis and/or endothelial cell proliferation
JP4636883B2 (ja) * 2002-11-21 2011-02-23 中外製薬株式会社 薬物徐放担体
US20060228331A1 (en) * 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
AU2005203988B2 (en) * 2004-01-07 2010-11-11 Seikagaku Corporation Hyaluronic acid derivative and drug containing the same
WO2005085294A1 (ja) * 2004-03-05 2005-09-15 Denki Kagaku Kogyo Kabushiki Kaisha ヒアルロン酸−メトトレキサート結合体
JP5060131B2 (ja) * 2004-09-07 2012-10-31 中外製薬株式会社 水溶性ヒアルロン酸修飾物の製造方法
US8937052B2 (en) * 2005-07-27 2015-01-20 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
IE20060049A1 (en) * 2006-01-25 2007-08-08 Eurand Pharmaceuticals Ltd A novel drug delivery system: use of hyaluronic acid as a carrier moleclue for different classes of therapeutic active agents
WO2008134528A1 (en) * 2007-04-25 2008-11-06 Board Of Regents, The University Of Texas System Anti-cancer agent-hyaluronic acid conjugate compositions and methods
US20100210509A1 (en) * 2007-10-09 2010-08-19 Postech Academy-Industry Foundation Long acting hyaluronic acid - peptide conjugate
US20090170195A1 (en) * 2007-12-28 2009-07-02 Kent State University Curcumin-hyaluronan compounds
JP5746629B2 (ja) * 2008-10-10 2015-07-08 ポリアクティヴァ・プロプライエタリー・リミテッド 生分解性ポリマー−生物活性部分の複合体
WO2010053140A1 (ja) * 2008-11-05 2010-05-14 国立大学法人 東京医科歯科大学 ヒアルロン酸誘導体、およびその医薬組成物
SG174367A1 (en) * 2009-03-23 2011-10-28 Quark Pharmaceuticals Inc Compounds compositions and methods of treating cancer and fibrotic diseases
US20120082717A1 (en) * 2009-06-05 2012-04-05 Snu R&Db Foundation Complex, multilayer using the same, and device coated with the multilayer
EP2488207A4 (en) * 2009-10-13 2015-06-10 Rexahn Pharmaceuticals Inc POLYMERIC SYSTEMS FOR ADMINISTERING ANTICANCER AGENTS
EP2496948B1 (en) * 2009-11-05 2018-01-10 University of Virginia Patent Foundation Compositions and methods for detecting plectin-1 as a biomarker for cancer
CN101732728B (zh) * 2010-01-25 2012-11-14 中国药科大学 抗炎药物-多糖偶联物及其药物组合物的制备和应用
WO2011130476A2 (en) * 2010-04-16 2011-10-20 The Research Foundation Of State University Of New York Polymer-based therapeutic agents
AU2011255647A1 (en) * 2010-05-18 2012-11-15 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
ES2635087T3 (es) * 2011-03-03 2017-10-02 Chugai Seiyaku Kabushiki Kaisha Derivado de ácido hialurónico modificado con ácido amino-carboxilico
ES2665254T3 (es) * 2011-07-12 2018-04-25 Holy Stone Healthcare Co., Ltd. Composiciones que comprenden ácido hialurónico para tratamiento y prevención de enfermedades relacionadas con las mucosas
JP6453214B2 (ja) * 2013-07-10 2019-01-16 生化学工業株式会社 グリコサミノグリカン誘導体及びその製造方法
US9572832B2 (en) * 2013-08-29 2017-02-21 Holy Stone Healthcare Co., Ltd. Compound of glycosaminoglycan and its fabrication method as well as application

Also Published As

Publication number Publication date
US20150065450A1 (en) 2015-03-05
DK3038656T3 (da) 2021-10-11
AU2014314536A1 (en) 2016-04-07
EP3038660A1 (en) 2016-07-06
EA201992517A2 (ru) 2020-03-31
AU2019268085A1 (en) 2019-12-12
US20150065446A1 (en) 2015-03-05
CA3133853C (en) 2023-03-07
CN110590971A (zh) 2019-12-20
HUE056434T2 (hu) 2022-02-28
AU2019268087B2 (en) 2020-09-10
ES2851973T3 (es) 2021-09-09
US20170151336A1 (en) 2017-06-01
CN113893354A (zh) 2022-01-07
CA2921830C (en) 2022-03-08
EA201992517A3 (ru) 2020-05-31
JP6433494B2 (ja) 2019-02-06
TWI526212B (zh) 2016-03-21
EA034600B1 (ru) 2020-02-25
CA3133859A1 (en) 2015-03-05
US9572832B2 (en) 2017-02-21
AU2019268087A1 (en) 2019-12-12
US11229665B2 (en) 2022-01-25
AU2019268085B2 (en) 2021-01-07
TW201509421A (zh) 2015-03-16
TW201509422A (zh) 2015-03-16
HK1223291A1 (zh) 2017-07-28
EA038422B1 (ru) 2021-08-26
EA038278B1 (ru) 2021-08-04
US20190275164A1 (en) 2019-09-12
CN105324132B (zh) 2020-07-21
WO2015031425A1 (en) 2015-03-05
US20240238329A9 (en) 2024-07-18
AU2019201691A1 (en) 2019-04-04
EP3038660B1 (en) 2020-12-23
KR101790649B1 (ko) 2017-10-26
WO2015028172A1 (en) 2015-03-05
EP3038660A4 (en) 2017-05-03
MY180502A (en) 2020-11-30
AU2014311302A1 (en) 2016-01-21
EA201690487A1 (ru) 2016-11-30
CN105324132A (zh) 2016-02-10
PT3038656T (pt) 2021-10-15
KR20160048905A (ko) 2016-05-04
JP2016525515A (ja) 2016-08-25
BR112016004357B1 (pt) 2022-09-27
US10342878B2 (en) 2019-07-09
CA2921830A1 (en) 2015-03-05
US20220111062A1 (en) 2022-04-14
JP2016529362A (ja) 2016-09-23
BR112016004357A2 (ru) 2017-08-01
AU2014314536B2 (en) 2019-11-07
KR102283978B1 (ko) 2021-08-02
EP3038656A1 (en) 2016-07-06
EP3038656B1 (en) 2021-08-18
KR20160014690A (ko) 2016-02-11
PL3038656T3 (pl) 2022-01-10
BR112015032529A2 (pt) 2017-07-25
AU2019201691B2 (en) 2019-10-03
EA201992518A3 (ru) 2020-05-31
CA3133853A1 (en) 2015-03-05
CA3133859C (en) 2023-03-14
CN114010796A (zh) 2022-02-08
EA201992518A2 (ru) 2020-03-31
AU2017204619A1 (en) 2017-07-27
BR112015032529B1 (pt) 2022-06-21
TWI577378B (zh) 2017-04-11
ES2893329T3 (es) 2022-02-08
HK1225993A1 (zh) 2017-09-22
EA031285B1 (ru) 2018-12-28
JP6404925B2 (ja) 2018-10-17
CN105579067A (zh) 2016-05-11
LT3038656T (lt) 2021-12-10

Similar Documents

Publication Publication Date Title
EA201501166A1 (ru) Соединение гликозаминогликана, способ его получения и применение
CY1120429T1 (el) Παραγωγα κιναζολινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων και αλλων νοσων
EA201492290A1 (ru) Составы и способы для вагинальной доставки антипрогестинов
EA201492052A1 (ru) Лечение миелосупрессии
EA201590622A1 (ru) Конъюгаты для доставки лекарственного средства, содержащие не встречающиеся в природе аминокислоты, и способы применения
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
CO6640206A2 (es) Formulación farmaceútica de una solución acuosa de un bufer de ácido glutámico y un anticuerpo
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
EA201590855A1 (ru) Соединения пирролопиримидина как ингибиторы киназ
EA201491330A1 (ru) Терапевтически активные соединения и способы их использования
EA201390682A1 (ru) Спирооксиндольные антагонисты mdm2
NZ720736A (en) Antibody drug conjugates (adcs) with kinesin spindel protein (ksp)
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
EA201300558A1 (ru) Соединения и способы для купирования боли
UA109991C2 (xx) Карбаматні сполуки, їх отримання і застосування
EA201590663A1 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ И ДРУГИХ ЗАБОЛЕВАНИЙ
MD20150035A2 (ru) Ингибиторы тирозинкиназы Брутона
EA201391616A1 (ru) Применение тиазолидных соединений для предотвращения и лечения вирусных заболеваний, рака и заболеваний, вызванных внутриклеточными инфекциями
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
BR112014011744A2 (pt) formulação de ação sustentável da forma 2 de ciclosporina
EA201491702A1 (ru) Оптимизированные терапевтические агенты для подкожного введения
EA201391702A1 (ru) Интраназальные тестостероновые составы с пониженной дозировкой в виде геля и их применение для лечения аноргазмии или гипоактивного расстройства сексуального желания
EA201591450A1 (ru) Фармацевтический состав, содержащий гликозаминогликан
EA201591653A1 (ru) Композиции для лечения глазных расстройств с применением дипиридамола